Net income jumped 285.2%, from $938.0M to $3.6B. That is the oddest number in AbbVie’s latest filing, and the easy reading is obvious: the drugmaker is turning a $17.0B revenue quarter into much more profit than it did a year ago.
Operating income rose 31.4% to $6.4B, lifting the operating margin to 37.9% from 31.7%. Shares closed at $250.88 on July 31, down 2.6% for the day. The filing itself offers a less tidy measure of the improvement: cash on hand increased only $100M, to $6.6B.
The tension is not that AbbVie failed to make cash. Operating cash flow reached $7,265M in the six months ended June 30, up from $6,788M. It is that capital spending consumed a larger share of revenue, while free-cash-flow margin declined by 1 percentage point.
AbbVie attributes the operating-cash increase to stronger results from operations and lower litigation payments, with timing in working capital and higher contingent-consideration payments working the other way.
"Operating cash flows for the six months ended June 30, 2026 increased compared to the prior year primarily due to increased results from operations driven by higher net revenues and lower payments related to litigation matters partially offset by timing of working capital and higher payments of contingent consideration liabilities."
AbbVie, Form 10-Q, filed Aug. 3, 2026
That cash-flow increase also names a contributor that is not simply product demand: lower litigation payments. AbbVie does not quantify how much of the improvement came from that item in the excerpt, leaving the cash increase partly tied to a payment comparison.
The business underneath it is growing, though not in one smooth line. Elahere revenue increased 32% for the three months ended June 30, primarily on increased demand, while Venclexta revenue rose 10%. Imbruvica fell 29% for the quarter, driven by unfavorable pricing, lower US demand, and decreased collaboration revenue. The smaller product lines were mixed, including a decline for Juvederm.
Gross margin also improved. AbbVie said higher revenue against lower fixed costs, driven mainly by reduced amortization of intangible assets, lifted gross margin as a percentage of revenue.
"Gross margin as a percentage of net revenues increased for the three and six months ended June 30, 2026 compared to the prior year primarily due to higher net revenues compared to lower fixed costs primarily driven by decreased amortization of intangible assets."
AbbVie, Form 10-Q, filed Aug. 3, 2026
The filing points to two separate contributors: stronger demand in some products added revenue, while a lower amortization burden increased gross margin on the income statement. The 285.2% net-income jump therefore needs a little bookkeeping around it.
AbbVie’s next quarterly report will put the unresolved piece on the page: operating cash flow alongside capital spending and the amount of litigation payments. Until then, the quarter shows more profit alongside higher capital intensity in cash conversion.
AbbVie reported higher revenue and operating income, while lower litigation payments and increased capital spending shaped the period’s cash flow.